Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Kluge

Interventional Cardiology Eau Claire, WI Doctor of Osteopathy

NPI 1861613523 CMS profile 220354

3802 Oakwood Mall Dr, Eau Claire, WI 54701

Open in the dashboard

General payments

$4,995

75 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Kluge of Eau Claire, WI is reported in the CMS Open Payments database as having received $4,995 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33 1
2024 General $124 4
2023 General $1,732 23
2022 General $206 6
2021 General $129 5
2020 General $74 4
2019 General $2,696 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Kluge
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Peter Kluge were reported at $33. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Peter Kluge Interventional Cardiology median Middle half National median
2019 $2,696 $1,097 $329–$3,048 $163
2020 $74 $473 $161–$1,480 $114
2021 $129 $677 $233–$1,827 $132
2022 $206 $978 $333–$2,724 $149
2023 $1,732 $1,136 $382–$2,986 $160
2024 $124 $1,181 $395–$3,326 $164
2025 $33 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $2,655 33 payments
  2. Abbott Laboratories $2,125 35 payments
  3. Medtronic, Inc. $110 2 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $57 3 payments
  5. Boston Scientific Corporation $33 1 payment
  6. Biotronik Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,298 10 payments
  2. Food and Beverage $1,682 64 payments
  3. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. Edwards SAPIEN 3 Transcatheter Heart Valve $2,555 28 payments
  2. Fortify Assura $1,421 12 payments
  3. GALLANT Cardiac Rhythm Management $298 7 payments
  4. ASSURITY $104 4 payments
  5. Mitra Clip system $73 1 payment
  6. Confirm Rx $71 3 payments
  7. SYMPLICITY G3 $67 1 payment
  8. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $60 3 payments
  9. GALLANT Cardiac Rhythm Management $58 3 payments
  10. LifeVest $57 3 payments
  11. Other $290 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,556

Median for Interventional Cardiology: 2,236

Drug cost

$335,447

Median for Interventional Cardiology: $380,412

Branded share of claims

29.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 162 $177,142
Xarelto Rivaroxaban Brand 66 $57,516
Jardiance Empagliflozin Brand 54 $47,132
Entresto Sacubitril/Valsartan Brand 14 $19,224
Multaq Dronedarone Hcl Brand 14 $17,322
Dofetilide Generic 14 $2,642
Metoprolol Succinate Generic 154 $2,198
Ezetimibe Generic 82 $1,730
Losartan Potassium Generic 135 $1,469
Clopidogrel Clopidogrel Bisulfate Brand 126 $1,458

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$82,820

Medicare's payments for the services billed

Medicare patients

1,341

Average age 77

Services billed

1,981

628 women, 713 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 51%
Atrial fibrillation 43%
Heart failure 36%
Diabetes 32%
Chronic kidney disease 32%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record